Form 4: Syros Pharmaceuticals CEO Chee Conley Reports Stock Transactions
SEC Form 4 Filing
Syros Pharmaceuticals' CEO, Chee Conley, reports the vesting of restricted stock units and subsequent stock transactions.
Summary
- On October 31, 2024, Chee Conley, the President and CEO of Syros Pharmaceuticals, executed transactions involving the company's common stock.
- Conley acquired 17,000 shares of common stock through the vesting of restricted stock units.
- Simultaneously, Conley disposed of 8,707 shares to cover tax withholding obligations at a price of $2.09 per share.
- Following these transactions, Conley directly owns 130,797 shares of Syros Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for executives to receive stock-based compensation and subsequently manage their holdings for tax purposes.
Key Dates
| Date | Description |
|---|---|
| October 6, 2022 | Date of restricted stock unit award grant. |
| October 31, 2023 | First vesting date (50%) of restricted stock units. |
| October 31, 2024 | Date of stock transactions: vesting of 17,000 restricted stock units and disposal of 8,707 shares for tax withholding. |
| November 04, 2024 | Date of Form 4 filing. |
Keywords
Syros Pharmaceuticals, Chee Conley, stock transactions, restricted stock units, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.